NR4A1 and breast cancer: This cohort study analyzed 823 399 patients with breast cancer and showed that patients with single hormone receptor–positive subtypes had worse breast cancer–specific survival (BCSS) than patients with double hormone receptor–positive subtypes but better BCSS than patients with double hormone receptor–negative subtypes, and the differences were statistically significant.